Search results
Results from the WOW.Com Content Network
Lipoatrophy is the term describing the localized loss of fat tissue. This may occur as a result of subcutaneous injections of insulin in the treatment of diabetes , from the use of human growth hormone or from subcutaneous injections of copaxone used for the treatment of multiple sclerosis .
45 (10): 850–2. PMID 11077638. Meyer L, Hadjadj S, Guerci B, Delbachian I, Ziegler O, Drouin P (1998). "Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion". Diabetes Metab. 24 (6): 544–6. PMID 9932222
Lipoatrophy is most commonly seen in patients treated with thymidine analogues and other older HIV drug treatments such as the nucleoside reverse transcriptase inhibitors [NRTIs] [9] like zidovudine (AZT) and stavudine (d4T). [10] Other lipodystrophies manifest as lipid redistribution, with excess, or lack of, fat in various regions of the body ...
A drug treatment for type 2 diabetes; belongs to a class of drugs called biguanides. First-line pharmacotherapy for type 2 diabetes mellitus. Mg/dL Milligrams per deciliter. How much glucose (sugar) is in a specific amount of blood. In self-monitoring of blood glucose, test results are given as the amount of glucose in milligrams per deciliter ...
Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. [7] It is used when dietary changes, exercise, and weight loss are not enough. [4]
Alogliptin, sold under the brand names Nesina and Vipidia, [2] [3] is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. [4] Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. [1]
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. [1] [2] Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet. [8] [9] It is generally less preferred than metformin and sulfonylureas as an initial treatment.